Ana Rita Teixeira Marques

Ana Rita Teixeira Marques


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ATAna Teixeira-Marques
Ana Teixeira-Marques
CLCatarina Lourenço
Catarina Lourenço
MOMiguel Carlos Oliveira
Miguel Carlos Oliveira
Rui HenriqueRui Henrique
Rui Henrique
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Bladder cancer (BC) is the 10th most frequently diagnosed cancer worldwide. Although urine cytology and cystoscopy are current standards for BC diagnosis, both have limited sensitivity to detect low-grade and small tumors. Moreover, effective prognostic biomarkers are lacking. Extracellular vesicles (EVs) are lipidic particles that contain nucleic acids, proteins, and metabolites, which are released by cells into the extracellular space, being crucial effectors in intercellular communication. These particles have emerged as potential tools carrying biomarkers for either diagnosis or prognosis in liquid biopsies namely urine, plasma, and serum. Herein, we review the potential of liquid biopsies EVs’ cargo as BC diagnosis and prognosis biomarkers. Additionally, we address the emerging advantages and downsides of using EVs within this framework.

26 August 2025 in Talanta
Verified
Journal Article
Open access
ÂCÂngela Carapito
Ângela Carapito
VFV.S. Fernandes Ferreira
V.S. Fernandes Ferreira
Ferreira AntonioFerreira Antonio
Ferreira Antonio
ATAna Teixeira-Marques
Ana Teixeira-Marques
Rui HenriqueRui Henrique
Rui Henrique
Paula Guedes de PinhoPaula Guedes de Pinho
Paula Guedes de Pinho
Early detection of bladder cancer (BC) remains a major clinical challenge due to the limitations of current diagnostic methods, which are often invasive, expensive, or insufficiently sensitive, particularly for early-stage disease. Metabolomics approaches, when integrated with machine learning (ML) techniques, offer a powerful platform for identifying novel, non-invasive biomarkers. In this study, urinary volatile organic compounds (VOCs) were analysed from 87 BC patients and 90 age- and sex-matched cancer-free controls using headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry (HS-SPME/GC-MS). Of the 90 VOCs identified, 27 were selected and used to train five ML algorithms-random forest (RF), support vector machine (SVM), partial least squares-discriminant analysis (PLS-DA), extreme gradient boosting (XGBoost), and k-nearest neighbors (k-NN). Model performance was evaluated using cross-validation and an independent validation set, with metrics including area under the curve (AUC), sensitivity, specificity, and accuracy. RF achieved the highest performance using all 27 features (AUC = 0.913; sensitivity, specificity, and accuracy = 85 %). After feature selection, an eight-VOC panel improved performance on the validation set (AUC = 0.872; sensitivity = 89 %, specificity = 92 %, accuracy = 91 %). The panel included ketones, aldehydes, a short fatty alcohol, and a phenol compound-seven elevated in BC, and one (acetone) decreased. This panel outperformed FDA-approved urinary assays and closely matched the specificity of urine cytology. These findings underscore the promise of VOC-based urinary biomarkers, in combination with ML, for the non-invasive detection of BC. Further large-scale validation studies are essential to confirm diagnostic utility and enable clinical translation.

7 October 2021 in Epigenomics
Verified
Journal Article
Closed access
DMDiana Montezuma
Diana Montezuma
ATAna Teixeira-Marques
Ana Teixeira-Marques
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Rui HenriqueRui Henrique
Rui Henrique